Para: A 4-month, Prospective, Open-label, Multi-center Phase IV Study to Assess Response to Fingolimod Initiation According to Coping Profile in Adult Patients With Highly Active Relapsing Remitting Multiple Sclerosis in France.
Phase of Trial: Phase IV
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms GRACE
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Dec 2012 Planned End Date changed from 1 Jul 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 23 Nov 2011 Planned end date changed from 1 Apr 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History